The FDA Updated Lay's Potato Chip Recall to Its Most Serious Level
According to the FDA, a Class I recall is "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death." It is the most serious classification out of a possible three.
The details of the recall are otherwise unchanged. The impacted chips were sold at select retailers and e-commerce distributors in Oregon and Washington. They were available for purchase as early as Nov. 3 and bear the 'Guaranteed Fresh' date of Feb. 11, 2025.
Additionally, the recalled Classic Potato Chips have the UPC 28400 31041 and both the 'Guaranteed Fresh' date of Feb. 5, 2025, and either Manufacturing Code 6462307xx or 6463307xx.
No other Frito-Lay products or Lay's chips or sizes are affected by this recall.
If you have the recalled chips—and have a milk allergy or sensitivity—you should not consume them. Instead, throw them away or return them to the place of purchase for a refund.
If you don't have a milk allergy or sensitivity, you can still consume the Lay's, as there is nothing inherently unsafe about the chips. Frito-Lay is simply exercising caution by recalling the mislabeled packages.
If you have any questions regarding the recall, you can contact Frito-Lay at 1-800-352-4477, Monday to Friday, from 9 a.m. to 4:30 p.m. CST.
Read the original article on ALLRECIPES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
a minute ago
- Epoch Times
FDA Approves Weight Loss Drug Wegovy for Liver Disease
The Food and Drug Administration has approved a weight loss drug called Wegovy for a liver disease, the agency announced on Aug. 18. Wegovy is now approved for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that impacts approximately 6 percent of American adults, the FDA said in a statement.
Politico
9 minutes ago
- Politico
HHS embraces AI
EXAM ROOM The Department of Health and Human Services has emerged as the leader in artificial intelligence use among all federal agencies. In 2024, HHS reported 116 different ways to use AI for generating content and responses — up from just seven the year before, according to a report from the Government Accountability Office, which monitors agencies for Congress. The GAO reported 271 different AI tools in use last year. A recent analysis by the Bipartisan Policy Center, a think tank in Washington, reveals how three HHS agencies have implemented AI. Notably, they're largely using chatbots to help them work more efficiently. The Centers for Disease Control and Prevention: In 2023, the CDC launched ChatCDC, a bot built on OpenAI's large language models that can summarize meeting minutes, internal documents and studies. It also uses the bot to write code for data analysis. The CDC is experimenting with an updated version that uses more internal documents, but as of January, it hadn't yet been released. The Food and Drug Administration: The FDA has launched a chatbot to help staff respond to emails, summarize meeting minutes and perform a wide variety of basic tasks. While FDA Commissioner Marty Makary has promised faster regulatory review turnaround, staff have argued that the tool is prone to mistakes and incapable of assisting with the review process. The FDA has also experimented with using AI for an array of tasks, including labeling drugs and looking for data patterns and anomalies. The Centers for Medicare and Medicaid Services: CMS uses AI to prevent and detect fraud, waste and abuse and analyze prescription drug costs. The takeaway: HHS continues to lead the way for AI use. Health Secretary Robert F. Kennedy Jr. has said he sees digital technology and AI as key tools for improving health care outcomes and reducing costs. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Sen. Marsha Blackburn (R-Tenn.) is calling for an investigation into Meta following reporting that the company allowed its chatbots to 'engage a child in conversations that are romantic or sensual.' Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. INFLUENCERS A newly launched psychedelic medicine foundation wants to become the 'American Cancer Society of ibogaine access.' Mission Within Foundation, which officially launched today, plans to use the $2 million in funding it has secured from private donors and foundations to promote the psychedelic drug ibogaine, derived from an African shrub, as a mental health treatment. The Drug Enforcement Administration classifies ibogaine as a Schedule I drug with no currently acceptable medical use and a high risk of abuse. It can pose heart risks and has been linked to about two dozen deaths in recent decades. The foundation plans to lobby for safe and legal access to ibogaine treatment in the U.S. and offer fully funded psychedelic therapy retreats to veterans and frontline workers with post-traumatic stress disorder, traumatic brain injuries, depression and addiction. It will also team up with the Dell Medical School at the University of Texas on three ibogaine research studies. Who's who: Dr. Martín Polanco, who runs The Mission Within, a psychedelic medicine clinic in Tijuana, Mexico, is one of the foundation's founders. He's treated more than 5,000 people with traumatic brain injuries and mental health conditions like PTSD, including many veterans, using ibogaine and the psychedelic drug 5-MeO-DMT, a desert toad secretion. Polanco has the ear of Reps. Jack Bergman (R-Mich.) and Lou Correa (D-Calif.), co-founders of the Congressional Psychedelics Advancing Therapies Caucus, who've been working in Washington to advance psychedelic medicine. Correa traveled to Polanco's clinic in Tijuana last year to talk with him in person and see whether his work justified further research on the drugs in the U.S. The foundation, which is also advocating for psychedelic medicine more broadly, is supporting Correa and Bergman's Innovative Therapies Centers of Excellence Act, which the pair introduced in April. The bill seeks $30 million for Veterans Affairs Department research on psychedelic therapies and would create five centers of excellence to research alternative treatments for veterans. What's next: Texas Gov. Greg Abbott, a Republican, signed a law in June putting $50 million in state funding toward clinical trials of ibogaine as a mental health treatment. And the state budget Arizona's Democratic governor, Katie Hobbs, signed into law the same month included a commitment of $5 million for studying ibogaine. Mississippi plans to hold a joint hearing of the House and Senate Public Health and Human Services committees on ibogaine on August 28.
Yahoo
an hour ago
- Yahoo
Many people using OTC birth control pills previously used nothing, study finds
Two years after the U.S. Food and Drug Administration approved the first over-the-counter birth control pill, new research is looking at who's switching to it and why. In the study, published Monday in JAMA Network Open, researchers used survey data from 986 people, ages 15 to 45, in 44 states who obtained the over-the-counter pill either online or at a pharmacy. They found that a significant portion of users shifted to the over-the-counter pill from a less-effective method of birth control or from using no contraception at all. Of those surveyed, they found a 31.8 percentage point increase in use by people who previously used no contraceptive method. A 41 percentage point increase was seen in those who switched from a less-effective method, like condoms or emergency contraception. Opill, the over-the-counter, progestin-only pill from drugmaker Perrigo, provides an option for obtaining oral contraceptives without needing to first see a health care provider. Allowing people to access the pill without a prescription was done in hopes of reducing barriers to access, according to the FDA's news release at the time of approval, which noted that almost half of the 6.1 million pregnancies in the U.S. each year are unintended. The new research "is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help — those who face the greatest barriers to care," lead author Dr. Maria Rodriguez, professor of obstetrics and gynecology in the Oregon Health & Science University School of Medicine, said in a news release. Those accessing the over-the-counter pill were more likely than prescription users to be uninsured, younger (ages 15-20) and living in rural areas, according to the study. The most common reason people gave in the survey for choosing the OTC pill was that it didn't require an appointment, followed by those who said they didn't have a regular physician. "At a time when pregnancy is becoming even more dangerous in the United States — especially for people of color, those with low incomes, and those living in rural communities — our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said. Alaska Sen. Dan Sullivan on the Trump-Putin summit, sanctions and more Laufey on creating her own sound A robotics activist's remarkable crusade Solve the daily Crossword
